Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RCUS |
---|---|---|
09:32 ET | 94305 | 16.89 |
09:36 ET | 408 | 17.04 |
09:38 ET | 403 | 16.8 |
09:50 ET | 200 | 16.7 |
09:52 ET | 200 | 16.685 |
09:54 ET | 200 | 16.81 |
09:56 ET | 200 | 16.75 |
09:59 ET | 500 | 16.88 |
10:01 ET | 2379 | 16.97 |
10:03 ET | 2730 | 16.83 |
10:06 ET | 357 | 16.84 |
10:12 ET | 745 | 16.82 |
10:14 ET | 550 | 16.86 |
10:15 ET | 100 | 16.84 |
10:17 ET | 200 | 16.88 |
10:19 ET | 523 | 16.9 |
10:21 ET | 1493 | 16.91 |
10:26 ET | 1705 | 16.98 |
10:28 ET | 262 | 16.96 |
10:32 ET | 300 | 16.945 |
10:37 ET | 774 | 16.92 |
10:39 ET | 300 | 16.89 |
10:44 ET | 200 | 16.94 |
10:46 ET | 488 | 16.89 |
10:50 ET | 14351 | 16.895 |
10:51 ET | 1566 | 16.91 |
10:53 ET | 1171 | 16.88 |
10:55 ET | 300 | 16.8899 |
11:00 ET | 412 | 16.83 |
11:02 ET | 300 | 16.83 |
11:04 ET | 264 | 16.78 |
11:06 ET | 260 | 16.77 |
11:08 ET | 100 | 16.82 |
11:11 ET | 300 | 16.82 |
11:13 ET | 2688 | 16.81 |
11:15 ET | 327 | 16.79 |
11:18 ET | 587 | 16.75 |
11:20 ET | 700 | 16.77 |
11:22 ET | 459 | 16.78 |
11:24 ET | 538 | 16.765 |
11:26 ET | 100 | 16.72 |
11:27 ET | 564 | 16.76 |
11:29 ET | 624 | 16.73 |
11:31 ET | 200 | 16.71 |
11:33 ET | 400 | 16.65 |
11:36 ET | 1254 | 16.68 |
11:38 ET | 6111 | 16.76 |
11:40 ET | 674 | 16.82 |
11:42 ET | 300 | 16.815 |
11:44 ET | 200 | 16.82 |
11:47 ET | 100 | 16.8 |
11:49 ET | 866 | 16.845 |
11:51 ET | 356 | 16.82 |
11:54 ET | 300 | 16.78 |
11:58 ET | 100 | 16.77 |
12:00 ET | 3902 | 16.785 |
12:02 ET | 600 | 16.73 |
12:05 ET | 100 | 16.74 |
12:09 ET | 1126 | 16.8 |
12:12 ET | 1255 | 16.78 |
12:16 ET | 254 | 16.76 |
12:18 ET | 200 | 16.75 |
12:20 ET | 300 | 16.73 |
12:21 ET | 300 | 16.73 |
12:23 ET | 501 | 16.75 |
12:25 ET | 397 | 16.76 |
12:30 ET | 900 | 16.73 |
12:32 ET | 200 | 16.73 |
12:34 ET | 100 | 16.72 |
12:36 ET | 2244 | 16.63 |
12:38 ET | 405 | 16.63 |
12:39 ET | 1438 | 16.62 |
12:41 ET | 781 | 16.62 |
12:43 ET | 100 | 16.615 |
12:45 ET | 1350 | 16.62 |
12:48 ET | 100 | 16.6 |
12:50 ET | 1397 | 16.615 |
12:52 ET | 200 | 16.63 |
12:54 ET | 800 | 16.6425 |
12:56 ET | 200 | 16.64 |
12:57 ET | 2820 | 16.65 |
12:59 ET | 2656 | 16.61 |
01:01 ET | 733 | 16.58 |
01:03 ET | 1287 | 16.61 |
01:06 ET | 957 | 16.62 |
01:08 ET | 201 | 16.64 |
01:10 ET | 908 | 16.64 |
01:14 ET | 200 | 16.63 |
01:15 ET | 4048 | 16.65 |
01:17 ET | 100 | 16.65 |
01:19 ET | 200 | 16.66 |
01:21 ET | 200 | 16.68 |
01:24 ET | 2661 | 16.69 |
01:26 ET | 100 | 16.68 |
01:28 ET | 200 | 16.72 |
01:30 ET | 1161 | 16.7 |
01:32 ET | 789 | 16.66 |
01:33 ET | 100 | 16.67 |
01:35 ET | 1058 | 16.69 |
01:37 ET | 300 | 16.71 |
01:39 ET | 200 | 16.69 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Arcus Biosciences Inc | 1.5B | -5.4x | --- |
Ardelyx Inc | 1.4B | -21.5x | --- |
Gyre Therapeutics Inc | 1.3B | -15.9x | --- |
Nurix Therapeutics Inc | 1.6B | -8.7x | --- |
Xencor Inc | 1.5B | -7.3x | --- |
Arvinas Inc | 1.8B | -4.8x | --- |
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.5B |
---|---|
Revenue (TTM) | $247.0M |
Shares Outstanding | 91.4M |
Arcus Biosciences Inc does not pay a dividend. | |
Beta | 0.89 |
EPS | $-3.10 |
Book Value | $6.12 |
P/E Ratio | -5.4x |
Price/Sales (TTM) | 6.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -118.62% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.